Skip to main content Skip to main navigation menu Skip to site footer

Review on the induction of obesity in laboratory animals

  • Urmila Aswar ,
  • Rashmi Patil ,
  • Subhash Bodhankar ,


Abstract

Abstract

Valid animal models are initial essential for successful screening of novel therapeutic strategies against all types of diseases. Development or selection of an animal model that resembles the human disease process and symptoms is dependent on a robust knowledge of the natural history and pathogenesis of the disease. The use of animal models thus becomes to understand the underlying physiological and genetic basis of energy regulation, taste and smell perception and food choice behaviour. Obesity is chronic metabolic disorder results from multiple etiologies like genetic, physiological, epigenetic and environmental factors. Animal models of obesity include direct measurement of food intake to long-term studies in animals exhibiting continuous overconsumption of food containing high calories and fat. It is of prime importance that we must choose the right models with high face, construct and predictive validity. Failing to select and use appropriate animal models impede successful discovery and development of safer and more potent therapeutics and wastage of money and time. We have thus provided a short review on currently available animal models of obesity. We discuss different method of induction of obesity in laboratory animals as well as the transgenic animals used in antiobesity drug discovery.

 

Keywords: Cafeteria diet hyper caloric diets obesity laboratory animals

References

  1. References
  2. Parasuraman S, Wen LE. Animal Model for Obesity-An Overview. Systematic Reviews in Pharmacy. 2015;6(1):9.
  3. Kleinert M, Clemmensen C, Hofmann SM, Moore MC, Renner S, Woods SC, et al. Animal models of obesity and diabetes mellitus. Nature Reviews Endocrinology. 2018;14(3):140.
  4. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635.
  5. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. Jama. 2003;289(2):187-93.
  6. Su X, Ren Y, Li M, Zhao X, Kong L, Kang J. Prevalence of comorbidities in asthma and nonasthma patients: a meta-analysis. Medicine. 2016;95(22).
  7. Schelbert KB. Comorbidities of obesity. Primary Care: Clinics in Office Practice. 2009;36(2):271-85.
  8. Fritscher LG, Mottin CC, Canani S, Chatkin JM. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obesity surgery. 2007;17(1):95.
  9. Giannopoulos GA, Tzanakis NE, Rallis GE, Efstathiou SP, Tsigris C, Nikiteas NI. Staple line reinforcement in laparoscopic bariatric surgery: does it actually make a difference? A systematic review and meta-analysis. Surgical endoscopy. 2010;24(11):2782-8.
  10. Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Disease models & mechanisms. 2012;5(5):621-6.
  11. Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obesity Reviews. 2019.
  12. Onakpoya I, Lee J, Mahtani KR, Aronson JK, Heneghan CJ. Benefits and Harms of Mysimba®(Naltrexone+ Bupropion) in the Management of Overweight and Obesity: A Systematic Review and Meta-Analysis of Unpublished Clinical Study Reports. Available at SSRN 3307636. 2018.
  13. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nature Reviews Endocrinology. 2018;14(1):12.
  14. Sane R, Amin D, Koli V, Kore R, Paranjpe S, Mandole R, et al. Impact of Low-Carbohydrate Diet (LCD) and Obesity Management Program on Obese Patients. European Journal of Preventive Medicine. 2019;7(1):1-6.
  15. Mauro M, Taylor V, Wharton S, Sharma AM. Barriers to obesity treatment. European journal of internal medicine. 2008;19(3):173-80.
  16. Sweeting HN. Gendered dimensions of obesity in childhood and adolescence. Nutrition journal. 2008;7(1):1.
  17. Wang B, Charukeshi Chandrasekera P, J Pippin J. Leptin-and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Current diabetes reviews. 2014;10(2):131-45.
  18. Cleary MP, Zisk J. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. International journal of obesity. 1986;10(3):193-204.
  19. Bourgeois F, Alexiu A, Lemonnter D. Dietary-induced obesity: effect of dietary fats on adipose tissue cellularity in mice. British Journal of Nutrition. 1983;49(1):17-26.
  20. Andersen ME, Clewell III HJ, Gearhart J, Allen BC, Barton HA. Pharmacodynamic model of the rat estrus cycle in relation to endocrine disruptors. Journal of toxicology and environmental health. 1997;52(3):189-209.
  21. Chakraborty TR, Gomez V, Adhikari D, Chakraborty S. The synergism in hormonal and cellular changes in male mice on long term high fat exposure. Journal of the American College of Nutrition. 2018;37(4):328-35.
  22. Inui A. Obesity–a chronic health problem in cloned mice? Trends in pharmacological sciences. 2003;24(2):77-80.
  23. Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutrition research reviews. 2010;23(2):270-99.
  24. Buettner R, Schölmerich J, Bollheimer LC. Highâ€fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity. 2007;15(4):798-808.
  25. Sato M, Kawakami T, Kondoh M, Takiguchi M, Kadota Y, Himeno S, et al. Development of high-fat-diet-induced obesity in female metallothionein-null mice. The FASEB Journal. 2010;24(7):2375-84.
  26. La Russa D, Giordano F, Marrone A, Parafati M, Janda E, Pellegrino D. Oxidative Imbalance and Kidney Damage in Cafeteria Diet-Induced Rat Model of Metabolic Syndrome: Effect of Bergamot Polyphenolic Fraction. Antioxidants. 2019;8(3):66.
  27. Woldenâ€Hanson T, Gidal BE, Atkinson RL. Evaluation of a rat model of valproateâ€induced obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1998;18(5):1075-81.
  28. Von Diemen V, Trindade EN, Trindade MRM. Experimental model to induce obesity in rats. Acta Cirurgica Brasileira. 2006;21(6):425-9.
  29. Hahm S, Fekete C, Mizuno TM, Windsor J, Yan H, Boozer CN, et al. VGF is required for obesity induced by diet, gold thioglucose treatment, and agouti and is differentially regulated in pro-opiomelanocortin-and neuropeptide Y-containing arcuate neurons in response to fasting. Journal of Neuroscience. 2002;22(16):6929-38.
  30. Lutz TA, Woods SC. Overview of animal models of obesity. Current protocols in pharmacology. 2012;58(1):5.61. 1-5.. 18.
  31. Harada N, Hanaoka R, Horiuchi H, Kitakaze T, Mitani T, Inui H, et al. Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Scientific reports. 2016;6:23001.
  32. Houtkooper RH, Argmann C, Houten SM, Cantó C, Jeninga EH, Andreux PA, et al. The metabolic footprint of aging in mice. Scientific reports. 2011;1:134.
  33. Aswar U, Chepurwar S, Shintre S, Aswar M. Telmisartan attenuates diabetes induced depression in rats. Pharmacological reports. 2017;69(2):358-64.
  34. Kalshetty P, Aswar U, Bodhankar S, Sinnathambi A, Mohan V, Thakurdesai P. Antidepressant effects of standardized extract of Centella asiatica L in olfactory bulbectomy model. Biomedicine & Aging Pathology. 2012;2(2):48-53.
  35. Xie J-T, Mehendale SR, Li X, Quigg R, Wang X, Wang C-Z, et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2005;1740(3):319-25.
  36. Xie J, Zhou Y-P, Dey L, Attele A, Wu J, Gu M, et al. Ginseng berry reduces blood glucose and body weight in db/db mice. Phytomedicine. 2002;9(3):254-8.
  37. Tzur R, Rose-Kahn G, Adler JH, Bar-Tana J. Hypolipidemic, antiobesity, and hypoglycemic-hypoinsulinemic effects of β, β′-methyl-substituted hexadecanedioic acid in sand rats. Diabetes. 1988;37(12):1618-24.
  38. Radavelli-Bagatini S, Blair AR, Proietto J, Spritzer PM, Andrikopoulos S. The New Zealand obese mouse model of obesity insulin resistance and poor breeding performance: evaluation of ovarian structure and function. Journal of Endocrinology. 2011;209(3):307-15.
  39. Kim JH, Stewart TP, Zhang W, Kim HY, Nishina PM, Naggert JK. The Type 2 diabetes mouse model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obesity. Physiological genomics. 2005.
  40. Roth GS, Mattison JA, Ottinger MA, Chachich ME, Lane MA, Ingram DK. Aging in rhesus monkeys: relevance to human health interventions. Science. 2004;305(5689):1423-6.
  41. Pan H, Fu C, Huang L, Jiang Y, Deng X, Guo J, et al. Anti-obesity effect of chitosan oligosaccharide capsules (COSCs) in obese rats by ameliorating leptin resistance and adipogenesis. Marine drugs. 2018;16(6):198.
  42. Panchal SK, Poudyal H, Iyer A, Nazer R, Alam A, Diwan V, et al. High-carbohydrate high-fat diet–induced metabolic syndrome and cardiovascular remodeling in rats. Journal of cardiovascular pharmacology. 2011;57(1):51-64.
  43. Pereira-Silva DC, Machado-Silva RP, Castro-Pinheiro C, Fernandes-Santos C. Does gender influence cardiovascular remodeling in C57BL/6J mice fed a high-fat, high-sucrose, high-salt diet? bioRxiv. 2018:367524.

How to Cite

Aswar, U., Patil, R., & Bodhankar, S. (2019). Review on the induction of obesity in laboratory animals. Diabesity, 5(4). https://doi.org/10.15562/diabesity.2019.58
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
131

Total
65

Share